SCHEMBL26048944

SCHEMBL26048944

CCCCCOC1CN(C(=O)OC(C)(C)C)C1

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
NR1H2 P55055 1/20 0.47
PRMT5 O14744 1/20 0.41
WDR77 Q9BQA1 1/20 0.41
USP2 O75604 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
PDE4D Q08499 2/20 0.38
CNR2 P34972 1/20 0.38
PDE4A P27815 1/20 0.38
PDE4B Q07343 1/20 0.38
PDE4C Q08493 1/20 0.38
NAMPT P43490 1/20 0.37
SPHK1 Q9NYA1 1/20 0.37
MEN1 O00255 1/20 0.36
ALDH1A1 P00352 1/20 0.36
MAPT P10636 1/20 0.36
KMT2A Q03164 1/20 0.36
GPR119 Q8TDV5 3/20 0.36
HPGD P15428 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20129179 0.95 NR1H2 (0.48) NR1H2PRMT5WDR77USP2SMN1; SMN2
SCHEMBL20128969 0.94 NR1H2 (0.43) NR1H2PRMT5WDR77PDE4DPDE4A
SCHEMBL27097799 0.90 NR1H2 (0.43) NR1H2PRMT5WDR77USP2SMN1; SMN2
SCHEMBL20129034 0.90 NR1H2 (0.43) NR1H2PRMT5WDR77USP2SMN1; SMN2
SCHEMBL16419552 0.89 NR1H2 (0.50) NR1H2PRMT5WDR77USP2SMN1; SMN2
SCHEMBL28959326 0.88 NR1H2 (0.50) NR1H2PRMT5WDR77USP2SMN1; SMN2
SCHEMBL27097864 0.87 NR1H2 (0.43) NR1H2PRMT5WDR77USP2SMN1; SMN2
SCHEMBL26495742 0.87 NR1H2 (0.43) NR1H2PRMT5WDR77USP2SMN1; SMN2
SCHEMBL20129252 0.87 NR1H2 (0.43) NR1H2PRMT5WDR77USP2SMN1; SMN2
SCHEMBL22907261 0.87 NR1H2 (0.46) NR1H2PRMT5WDR77USP2SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230250097-A1 BENZO[C][2,6]NAPHTHYRIDINE DERIVATIVES, COMPOSITIONS AND THERAPEUTIC USES THEREOF Apollo Therapeutics Limited (GB) 2023-08-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230250097-A1 BENZO[C][2,6]NAPHTHYRIDINE DERIVATIVES, COMPOSITIONS AND THERAPEUTIC USES THEREOF CSNK1A1, CSNK1D, CSNK2A1 NR1H2 658/4885PRMT5 2375/4885WDR77 2418/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.